In vitro and in vivo applications of alginate/iron oxide nanocomposites for theranostic molecular imaging in a brain tumor model

RSC Advances ◽  
2015 ◽  
Vol 5 (109) ◽  
pp. 90061-90064 ◽  
Author(s):  
Chia-Hao Su ◽  
Fong-Yu Cheng
Keyword(s):  
Brain Tumor ◽  
Iron Oxide ◽  
Molecular Imaging ◽  
Tumor Model ◽  
Brain Tumor Model ◽  
Us Fda

A novel nanocomposite composed of highly safe and US-FDA-approved Fe3O4 NPs and alginate shows significant anti-brain tumor activity.

Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo

2005 ◽  
Vol 13 (6) ◽  
pp. 337-343 ◽  
Author(s):  
Bhawna Gupta ◽  
Tatiana S. Levchenko ◽  
Dmitry A. Mongayt ◽  
Vladimir P. Torchilin
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumor ◽  
Tumor Cells ◽  
Tumor Model ◽  
Subcutaneous Tumor ◽  
Brain Tumor Cells

scholarly journals Analysis of Fluorescence Decay Kinetics of Indocyanine Green Monomers and Aggregates in Brain Tumor Model In Vivo

Nanomaterials ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 3185
Author(s):  
Dina Farrakhova ◽  
Igor Romanishkin ◽  
Yuliya Maklygina ◽  
Lina Bezdetnaya ◽  
Victor Loschenov
Keyword(s):  
Brain Tumor ◽  
Indocyanine Green ◽  
Fluorescence Lifetime ◽  
Tumor Model ◽  
Fluorescence Decay ◽  
Decay Kinetics ◽  
Lifetime Analysis ◽  
Fluorescence Decay Kinetics ◽  
Brain Tumor Model

Spectroscopic approach with fluorescence time resolution allows one to determine the state of a brain tumor and its microenvironment via changes in the fluorescent dye’s fluorescence lifetime. Indocyanine green (ICG) is an acknowledged infra-red fluorescent dye that self-assembles into stable aggregate forms (ICG NPs). ICG NPs aggregates have a tendency to accumulate in the tumor with a maximum accumulation at 24 h after systemic administration, enabling extended intraoperative diagnostic. Fluorescence lifetime analysis of ICG and ICG NPs demonstrates different values for ICG monomers and H-aggregates, indicating promising suitability for fluorescent diagnostics of brain tumors due to their affinity to tumor cells and stability in biological tissue.

scholarly journals Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: Characterization In Vitro

2012 ◽  
Vol 3 ◽  
pp. 166-174 ◽  
Author(s):  
Emanuela Binello ◽  
Zulekha A. Qadeer ◽  
Harini P. Kothari ◽  
Luni Emdad ◽  
Isabelle M. Germano
Keyword(s):  
Brain Tumor ◽  
Mouse Brain ◽  
Tumor Model ◽  
Immunocompetent Mouse ◽  
Brain Tumor Model

scholarly journals Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model

Oncotarget ◽  
2015 ◽  
Vol 6 (39) ◽  
pp. 42091-42104 ◽  
Author(s):  
Elisabetta Benedetti ◽  
Andrea Antonosante ◽  
Michele d’Angelo ◽  
Loredana Cristiano ◽  
Renato Galzio ◽  
...  
Keyword(s):  
Cell Death ◽  
Brain Tumor ◽  
Tumor Growth ◽  
Tumor Model ◽  
Autophagic Cell Death ◽  
Primary Cells ◽  
Human Glioblastoma ◽  
Brain Tumor Model

Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea—resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma

2004 ◽  
Vol 101 (5) ◽  
pp. 826-831 ◽  
Author(s):  
Ryuta Saito ◽  
John Bringas ◽  
Hanna Mirek ◽  
Mitchel S. Berger ◽  
Krys S. Bankiewicz
Keyword(s):  
Drug Resistance ◽  
Tumor Model ◽  
Growth Patterns ◽  
Invasive Growth ◽  
Content Type ◽  
Rat Glioma ◽  
Brain Tumor Model ◽  
Fine Print

Object. Chemotherapy is suspected of having an effect on the generation of phenotypical heterogeneity and the development of drug resistance in tumors. Recurrent gliomas feature drug resistance as well as greater invasive growth than original tumors. The authors investigated phenotypical changes in invasion observed in 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)—resistant sublines of the 9L rat gliosarcoma. Methods. Two established BCNU-resistant sublines, derived from 9L gliosarcoma cells by treating these cells with BCNU in vivo or in vitro, were used in the study. An in vitro examination confirmed the resistance of the cells to BCNU treatment. The cells were implanted into the striatum of Fisher 344 rats, and histological examinations were performed to compare the growth patterns of the resultant tumors. A new brain tumor model was established by implanting 9L-2 cells in Fisher 344 rats. The 9L-2 and BTRC-19 cells displayed a distinct increase in BCNU resistance compared with the 9L cells. Both BCNU-resistant sublines developed a tumor mass with invasive margins, which is not the case with 9L tumor models. The newly developed 9L-2 tumor model demonstrated 100% tumor uptake with consistent growth patterns. Conclusions. Cells that acquire drug resistance also demonstrated invasive growth. Because the 9L-2 and BTRC-19 cells were derived from 9L cells that had been treated with BCNU in vivo and in vitro, this change in phenotype was likely caused by the drug treatment, which may have implications for chemotherapy of gliomas. The tumor model that developed from the 9L-2 cells can be used as a model of a recurrent glioma, which features drug resistance and invasive growth.

Effects of Hyperglycemia on pH and Blood Flow In a Brain Tumor Model: An In Vivo Study

1989 ◽  
Vol 24 (12) ◽  
pp. S96
Author(s):  
S L Mitchell ◽  
B D Ross ◽  
H Merkle ◽  
M Garwood
Keyword(s):  
Blood Flow ◽  
Brain Tumor ◽  
Tumor Model ◽  
In Vivo Study ◽  
Brain Tumor Model
Sign in / Sign up

Export Citation Format

Share Document